Home
About Us
We are a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in the areas of Immunology and Rare Disease.
Our Approach
Our highly targeted clinical-stage therapeutics are founded on a strong scientific and clinical rationale that may enable accelerated clinical development and increased probability of clinical and regulatory success.
Our Pipeline
We are rapidly advancing a rich pipeline with the potential for broad clinical utility across Immunology and Rare Genetic Diseases.
Differentiating Attributes of Our Programs
- Novel mechanisms offering potential as first-in-class medications
- First available therapy and/or substantial improvement over existing therapies for serious diseases
- Targeted mechanisms of action with the potential for a favorable benefit-risk profile
- Candidates for accelerated clinical development and regulatory pathways
- Identified biomarkers and/or published clinical proof of concept increase the probability regulatory approval
- Associated biomarkers offer the potential for better patient identification and higher response rates
Recent News
Sep 6, 2022 7:00 am
Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage
Sep 1, 2022 7:00 am
Avalo to Present at the H.C. Wainwright Global Investment Conference
